Neuphoria Therapeutics Inc. (NEUP) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$3.28

From 52W high−78.67%

Volume39377.00

Market cap$17.91M

P/E (TTM)—

P/S (TTM)15.3x

Div yield—

Key dataOct 19, 2026

Open

$3.28

From 52W high

−78.67%

Volume

39377.00

Market cap

$17.91M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.2x

P/E (TTM)

—

RSI (14)

32.2

MomentumView details →

1D Return

+0.30%

YTD Return

−14.69%

SummaryUpdated Jun 1, 2026

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) is a clinical-stage biotechnology company founded on December 23, 2024, and headquartered in Burlington, Massachusetts. The company went public on December 16, 2021, and focuses on developing innovative therapies for individuals affected by neuropsychiatric disorders. As a relatively new entrant in the biotechnology sector, Neuphoria represents the emerging wave of specialized pharmaceutical companies targeting the complex intersection of neurology and psychiatry, an area that has historically been underserved by traditional drug development approaches.

Ask drillr about Neuphoria Therapeutics Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.2x

EV/Sales

−1.6x

P/S (TTM)

15.3x

P/B (TTM)

0.7x

ProfitabilityView details →

Gross Margin

43.54%

Net Margin

−1578.40%

EBITDA Margin

−1084.70%

ROE (TTM)

−75.34%

ROA (TTM)

−64.55%

Asset Turnover

0.04x

GrowthView details →

Revenue YoY

−79.03%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

−92.50%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+0.30%

YTD Return

−14.69%

1Y Return

−78.51%

RSI (14)

32.2

vs 50D SMA

−9.86%

vs 200D SMA

−21.08%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

27.85x

Quick Ratio

27.85x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.56

EPS Surprise

0.00%

Beats (12Q)

4/12

Next Q EPS Est

−$1.64

Avg Surprise (4Q)

−387.95%

Rev Surprise

17.41%

Financials snapshotView financials →

Revenue (TTM)

1.17M

Net Income (TTM)

−18.53M

Op. CF (TTM)

−12.91M

Latest newsMore news →

Scancell Holdings plc announces an all-share merger to acquire Neuphoria Therapeutics Inc., with the combined company to operate as Scancell and trade on Nasdaq under the symbol SCLT.89d ago

Neuphoria Therapeutics is in talks with Scancell Holdings plc about a possible combination.115d ago

Similar companies

Kyntra Bio, Inc.KYNB Sanai Health Industry Group Company Limited01889.HK PetMed Express, Inc.PETS Plus Therapeutics, Inc.CNSY Hoth Therapeutics, Inc.RKTO Pa Shun International Holdings Limited00574.HK Find similar companies →

Latest newsMore news →

Scancell Holdings plc announces an all-share merger to acquire Neuphoria Therapeutics Inc., with the combined company to operate as Scancell and trade on Nasdaq under the symbol SCLT.89d ago Neuphoria Therapeutics is in talks with Scancell Holdings plc about a possible combination.115d ago